BioLife Solutions completed the acquisition of remaining 90% stake in PanTHERA CryoSolutions for $16.5m.

BioLife Solutions, a supplier of cell processing tools and services for the cell and gene therapy market, completed the acquisition of remaining 90% stake in PanTHERA CryoSolutions, a designer and manufacturer of cryopreservation solutions for cells, tissues and organs in research and clinical markets, for $16.5m. "This acquisition is an extension of our strategy to strengthen BioLife's leadership position as a pure play consumables provider and enabler of advanced therapies. PanTHERA's differentiated IRI technology enhances our core capabilities in biopreservation, and their talented scientific team shares our commitment to deliver innovative, enabling solutions for the fast-growing CGT market," Roderick de Greef, BioLife Chairman and CEO.